Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.22 -0.8%	$1.32	$0.86 ▼ $3.78	$269.04M	0.31	3.25 million shs	1.61 million shs
ATYR aTyr Pharma	$4.98 -4.6%	$4.03	$1.46 ▼ $5.98	$464.60M	0.88	1.08 million shs	2.95 million shs
NTGN Neon Therapeutics	$3.07	$3.03	$0.88 ▼ $6.25	$88.93M	-0.81	516,108 shs	N/A
PROK ProKidney	$0.61 -8.2%	$0.81	$0.46 ▼ $2.59	$193.21M	1.36	638,278 shs	2.06 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	-0.81%	-10.95%	+15.09%	-23.75%	-52.16%
ATYR aTyr Pharma	-4.60%	-9.12%	+32.80%	+42.69%	+497,999,900.00%
NTGN Neon Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
PROK ProKidney	-8.20%	-38.56%	-14.72%	-40.00%	-75.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	3.5903 of 5 stars	4.5	3.0	0.0	0.0	1.5	3.3	0.6
ATYR aTyr Pharma	2.6034 of 5 stars	3.6	1.0	0.0	0.0	3.8	1.7	0.6
NTGN Neon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	1.699 of 5 stars	3.2	0.0	0.0	0.0	0.6	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.90	Moderate Buy	$8.44	592.17% Upside
ATYR aTyr Pharma	3.14	Buy	$20.20	305.62% Upside
NTGN Neon Therapeutics	0.00	N/A	N/A	N/A
PROK ProKidney	2.33	Hold	$4.50	642.57% Upside

Current Analyst Ratings Breakdown

Latest NTGN, ALLO, PROK, and ATYR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	ATYR aTyr Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$17.00 ➝ $25.00
6/4/2025	ATYR aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
5/19/2025	ATYR aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00 ➝ $35.00
5/15/2025	ALLO Allogene Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00
5/14/2025	ALLO Allogene Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$9.00 ➝ $7.00
5/14/2025	ALLO Allogene Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $10.00
5/14/2025	ALLO Allogene Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$10.00 ➝ $10.00
5/14/2025	ALLO Allogene Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
5/14/2025	ALLO Allogene Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$12.00 ➝ $9.00
5/14/2025	ALLO Allogene Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$20K	13,342.53	N/A	N/A	$2.01 per share	0.61
ATYR aTyr Pharma	$230K	1,927.04	N/A	N/A	$0.83 per share	6.00
NTGN Neon Therapeutics	N/A	N/A	N/A	N/A	$0.50 per share	N/A
PROK ProKidney	$80K	2,217.20	N/A	N/A	($3.41) per share	-0.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$257.59M	-$1.23	N/A	N/A	N/A	N/A	-52.98%	-41.28%	8/6/2025 (Estimated)
ATYR aTyr Pharma	-$64.02M	-$0.81	N/A	N/A	N/A	N/A	-87.09%	-64.77%	8/12/2025 (Estimated)
NTGN Neon Therapeutics	-$79.78M	-$2.86	N/A	N/A	N/A	N/A	-199.09%	-137.14%	N/A
PROK ProKidney	-$61.19M	-$0.60	N/A	N/A	N/A	N/A	N/A	-15.03%	8/8/2025 (Estimated)

Latest NTGN, ALLO, PROK, and ATYR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ALLO Allogene Therapeutics	-$0.28	-$0.28	N/A	-$0.28	$0.00 million	N/A
5/12/2025	Q1 2025	PROK ProKidney	-$0.16	-$0.13	+$0.03	-$0.13	N/A	$0.23 million
5/7/2025	Q1 2025	ATYR aTyr Pharma	-$0.19	-$0.17	+$0.02	-$0.17	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
ATYR aTyr Pharma	N/A	N/A	N/A	N/A	N/A
NTGN Neon Therapeutics	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	9.71	9.71
ATYR aTyr Pharma	0.01	7.79	7.79
NTGN Neon Therapeutics	0.43	1.58	3.00
PROK ProKidney	N/A	10.96	10.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
ATYR aTyr Pharma	61.72%
NTGN Neon Therapeutics	54.71%
PROK ProKidney	51.59%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
ATYR aTyr Pharma	3.70%
NTGN Neon Therapeutics	38.93%
PROK ProKidney	41.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	218.73 million	189.86 million	Optionable
ATYR aTyr Pharma	53	89.00 million	85.71 million	Optionable
NTGN Neon Therapeutics	102	28.97 million	N/A	Not Optionable
PROK ProKidney	3	292.70 million	171.26 million	Optionable

NTGN, ALLO, PROK, and ATYR Headlines

Recent News About These Companies

Hennion & Walsh Asset Management Inc. Has $740,000 Stake in ProKidney Corp. (NASDAQ:PROK)

June 8, 2025 | marketbeat.com

ProKidney quarterly loss grows as it nears two key milestones

May 15, 2025 | journalnow.com

ProKidney Reports First Quarter 2025 Financial Results and Business Highlights

May 12, 2025 | globenewswire.com

Another Big Office Landlord Tests Sales Climate

May 12, 2025 | bankerandtradesman.com

PROKIDNEY Earnings Preview: Recent $PROK Insider Trading, Hedge Fund Activity, and More

May 9, 2025 | nasdaq.com

Why ProKidney Corp.’s (PROK) Stock Is Down 6.09%

April 28, 2025 | aaii.com

Insider Buying: ProKidney Corp. (NASDAQ:PROK) Insider Purchases 387,393 Shares of Stock

April 25, 2025 | insidertrades.com

Why ProKidney Corp.’s (PROK) Stock Is Down 7.90%

April 17, 2025 | aaii.com

ProKidney Corp. (NASDAQ:PROK) Insider Buys $195,716.65 in Stock

April 17, 2025 | insidertrades.com

Greensboro’s Once Great Win Is Now A ProKidney Failure

April 16, 2025 | rhinotimes.com

Control Empresarial De Capital Buys 1,032,218 Shares of ProKidney Corp. (NASDAQ:PROK) Stock

April 15, 2025 | insidertrades.com

Why ProKidney Corp.’s (PROK) Stock Is Down 9.90%

April 10, 2025 | aaii.com

Why ProKidney Corp.’s (PROK) Stock Is Down 14.87%

April 8, 2025 | aaii.com

ProKidney Corp.

March 30, 2025 | wsj.com

Here's Why We're Watching ProKidney's (NASDAQ:PROK) Cash Burn Situation

March 27, 2025 | finance.yahoo.com

Down -38% in 4 Weeks, Here's Why You Should You Buy the Dip in PROKIDNEY CP (PROK)

March 21, 2025 | zacks.com

ProKidney reports larger loss in 2024 as production resumes

March 18, 2025 | journalnow.com

ProKidney reports FY24 EPS (62c), consensus (59c)

March 17, 2025 | markets.businessinsider.com

ProKidney Corp. Reports 2024 Financial Results and Milestones in Rilparencel Development for Chronic Kidney Disease

March 17, 2025 | quiverquant.com

ProKidney Reports Full Year 2024 Financial Results and Business Highlights

March 17, 2025 | globenewswire.com

Why ProKidney Corp.’s (PROK) Stock Is Down 10.96%

February 26, 2025 | aaii.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
By Leo Miller | June 14, 2025
View Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY
By Thomas Hughes | June 11, 2025
View Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY

NTGN, ALLO, PROK, and ATYR Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.22 -0.01 (-0.81%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$1.21 -0.01 (-0.82%)

As of 06:38 AM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

aTyr Pharma NASDAQ:ATYR

$4.98 -0.24 (-4.60%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$5.04 +0.06 (+1.31%)

As of 07:00 AM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Neon Therapeutics NASDAQ:NTGN

Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

ProKidney NASDAQ:PROK

$0.61 -0.05 (-8.20%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$0.60 0.00 (-0.50%)

As of 04:03 AM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time